Carl Landgren, MD
Hematology & Oncology · Miami, FLNPI 1972926871
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $330,997 of the $516,660 with a category attached, or 64.1%. 28 manufacturers reported payments, led by Amgen at 28.7% of the total. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $1865.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$148K
- Pfizer$49K
- Sanofi$47K
- Janssen Research & Development, LLC$42K
- GSK$37K
- Adaptive Biotechnologies Corporation$32K
- plus $162K from 22 others
Across 500 payments — averaging $94,687 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$35.2M
- Pfizer$7.4M
- Janssen Research & Development, LLC$2.3M
- Sanofi US Services Inc.$1M
- Bristol Myers Squibb$906K
- Menarini Silicon Biosystems, Inc.$427K
- plus $164K from 5 others
What the payments were for
- Consulting fees$330,99764%
- Speaking & faculty fees$142,91128%
- Travel & lodging$37,9947%
- Food & beverage$4,7581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $148,363 |
| Pfizer | 32 | $48,643 |
| Sanofi | 32 | $46,683 |
| Janssen Research & Development, LLC | 7 | $41,992 |
| GSK | 21 | $37,074 |
| Adaptive Biotechnologies Corporation | 21 | $31,757 |
| Regeneron | 18 | $22,559 |
| Johnson & Johnson | 26 | $20,240 |
| Bristol Myers Squibb | 10 | $19,966 |
| AbbVie | 7 | $16,100 |
| Merck | 8 | $14,666 |
| Karyopharm Therapeutics Inc. | 8 | $11,744 |
| E.r. Squibb & Sons, L.L.C. | 5 | $10,316 |
| Janssen Scientific Affairs, LLC | 7 | $8,937 |
| Beigene USA, Inc. | 1 | $7,875 |
| Sanofi-aventis U.S. LLC | 1 | $7,000 |
| The Binding Site Inc. | 7 | $5,484 |
| Beigene, Ltd. | 1 | $3,500 |
| AstraZeneca | 1 | $3,300 |
| Janssen Global Services, LLC | 3 | $2,440 |
| Dr.reddy's Laboratories,inc. | 1 | $2,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,485 |
| Gilead | 1 | $1,340 |
| Aadi Bioscience, Inc. | 2 | $1,275 |
| Celularity Inc. | 1 | $1,000 |
| Genentech, Inc. | 1 | $825 |
| Modernatx, Inc. | 1 | $67 |
| Tempus AI, Inc | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$516,660 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
- Gerald SoffMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.